Enzo's HPV test approved by New York health department

LabPulse.com staff writers
Apr 18, 2022
2020 07 29 23 56 6775 Hpv Infection 400

Enzo Biochem has received approval from the New York State Department of Health for the company's Ampiprobe molecular human papillomavirus (HPV) test.

Ampiprobe is the company's PCR-based test which can detect 14 high-risk HPV variants. The company said this approval positions it to pursue U.S. and international regulatory approvals.

Latest in Regulatory Approval
Alzheimers Tau Tangles Social
Roche, Lilly Alzheimer's blood test granted FDA breakthrough device designation
April 11, 2024
Breast Mammo Social
Roche's breast cancer CDx receives CE Mark
April 10, 2024
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
Computer Brain Hemisphere Social
FDA accepts 1st AI-based tool into Istand pilot program
January 26, 2024
Related Stories
Hpv Infection Social
HPV
Mailed HPV home test kits doubled cervical cancer screening rates in study
2019 05 17 20 09 8391 Hpv 400
HPV
Enzo launches RNA gene expression platform for HPV
2019 05 15 20 52 2340 Lab Pcr Tubes Dna 400
HPV
OmniPathology launches lab-developed test for HPV
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in Regulatory Approval
Roche, Lilly Alzheimer's blood test granted FDA breakthrough device designation
By LabPulse.com staff writers
The Alzheimer's blood test developed through a collaboration between Roche and Lilly has been granted a breakthrough device designation by the U.S. Food and Drug Administration (FDA).
April 11, 2024
Alzheimers Tau Tangles Social
Roche's breast cancer CDx receives CE Mark
By LabPulse.com staff writers
Roche has received the CE Mark for the first companion diagnostic (CDx) test to identify patients with HER2-low metastatic breast cancer who may be eligible for treatment with Enhertu.
April 10, 2024
Breast Mammo Social
Bio-Techne receives IVDR certification for chronic myeloid leukemia monitoring test
By LabPulse.com staff writers
Bio-Techne has announced that Asuragen, part of its molecular diagnostics division, has completed class C certification under the new European Union IVDR for its QuantideX qPCR BCR-ABL IS kit for monitoring chronic myeloid leukemia.
March 22, 2024
Blood Test Samples Lab Social
FDA accepts 1st AI-based tool into Istand pilot program
By LabPulse.com staff writers
A mental health assessment tool has become the first AI-powered tool to be accepted into the U.S. Food and Drug Administration's (FDA) Innovative Science and Technology Approaches for New Drugs (Istand) pilot program for advancing drug development.
January 26, 2024
Computer Brain Hemisphere Social
Sensorion receives clinical trial approval for congenital deafness gene therapy
By LabPulse.com staff writers
French biotech firm Sensorion has received approval to initiate a phase I and II clinical trial in France of SENS-501 (the OTOF-GT program), its gene therapy for gene-mediated hearing impairment.
January 22, 2024
Clinical Trial Data Network Social
Health Canada approves Pfizer’s hemophilia gene therapy
By LabPulse.com staff writers
Health Canada, Canada’s regulatory agency, has approved Pfizer's Beqvez (fidanacogene elaparvovec) as a gene therapy treatment for adults with moderately severe to severe hemophilia B.
January 3, 2024
Cell Gene Therapy Dna Social
Regulators to examine Thermo Fisher acquisition of Olink
By LabPulse.com staff writers
Shares of proteomics firm Olink dropped approximately 3% last week following the disclosure by the company that the U.K.’s regulatory body will investigate its pending acquisition by Thermo Fisher.
December 27, 2023
Regulation Wheel Social
U.K. regulators approve 'world-first' sickle-cell gene therapy
By Matt Limb
U.K. medical regulators have approved a “world-first” gene therapy that aims to cure two blood disorders: sickle cell disease and transfusion-dependent β-thalassemia. They are the first regulatory body to approve the treatment.
November 20, 2023
Sickle Cell Anemia2 Social
FDA plans to increase oversight of LDTs garner strong response
By Nick Paul Taylor
Plans to increase U.S. Food and Drug Administration (FDA) oversight of laboratory-developed tests (LDTs) have drawn a strong response from trade groups, individuals, and organizations.
November 17, 2023
Fda Sign Dc Social
BioMĂ©rieux receives CE Mark for biomarker assay for mild TBI
By LabPulse.com staff writers
BioMĂ©rieux has obtained the CE Mark for its assay to detect two biomarkers associated with mild traumatic brain injury (mTBI).
October 16, 2023
Football Player Concussion Social
Alzheimer’s drug approval poised to reshape APOE testing market
By Nick Paul Taylor
The U.S. Food and Drug Administration (FDA) approval of Biogen and Eisai’s Alzheimer’s disease drug Leqembi is likely to drive changes in the APOE testing market, according to an article in GenomeWeb.
September 25, 2023
Amyloid Plaque Alzheimer Social
Guardant 360 CDx receives approval in Japan for NSCLC
By LabPulse.com staff writers
The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved the Guardant360 CDx liquid biopsy test as a companion diagnostic for select patients with HER2-mutant NSCLC who are eligible for treatment with the antibody drug conjugate Enhertu.
September 7, 2023
Lung Cancer Hotspot Social
Page 1 of 5
Next Page